Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Elliott

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|November 3, 2021
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive casesAyalew Tefferi, Jaya Kittur, Faiqa Farrukh, et al.
Blood Cancer Journal|January 18, 2024
One thousand patients with essential thrombocythemia: the Mayo Clinic experienceNaseema Gangat, Omer Karrar, Aref Al-Kali, et al.
British Journal of Haematology|December 22, 2017
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosisAyalew Tefferi, Sahrish Shah, Mythri Mudireddy, et al.
Leukemia & Lymphoma|September 17, 2004
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombinMichelle A Elliott, Robert C Wolf, Christopher C Hook, et al.
Annals of Hematology|October 19, 2018
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapyOmar A Alkharabsheh, Salwa S Saadeh, Darci L Zblewski, et al.
Leukemia & Lymphoma|October 1, 2016
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromesPrashant Sharma, Shivani S Shinde, Moussab Damlaj, et al.
American Journal of Hematology|September 26, 2018
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelideAyalew Tefferi, Natasha Szuber, Rangit R Vallapureddy, et al.
Blood Advances|March 10, 2022
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular eventsNaseema Gangat, Natasha Szuber, Yamna Jadoon, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Blood Cancer Journal|March 12, 2021
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomesEvandro D Bezerra, Terra L Lasho, Christy M Finke, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|November 3, 2021
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive casesAyalew Tefferi, Jaya Kittur, Faiqa Farrukh, et al.
Blood Cancer Journal|January 18, 2024
One thousand patients with essential thrombocythemia: the Mayo Clinic experienceNaseema Gangat, Omer Karrar, Aref Al-Kali, et al.
British Journal of Haematology|December 22, 2017
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosisAyalew Tefferi, Sahrish Shah, Mythri Mudireddy, et al.
Leukemia & Lymphoma|September 17, 2004
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombinMichelle A Elliott, Robert C Wolf, Christopher C Hook, et al.
Annals of Hematology|October 19, 2018
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapyOmar A Alkharabsheh, Salwa S Saadeh, Darci L Zblewski, et al.
Leukemia & Lymphoma|October 1, 2016
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromesPrashant Sharma, Shivani S Shinde, Moussab Damlaj, et al.
American Journal of Hematology|September 26, 2018
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelideAyalew Tefferi, Natasha Szuber, Rangit R Vallapureddy, et al.
Blood Advances|March 10, 2022
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular eventsNaseema Gangat, Natasha Szuber, Yamna Jadoon, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Blood Cancer Journal|March 12, 2021
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomesEvandro D Bezerra, Terra L Lasho, Christy M Finke, et al.
Pageof 9